JPRN-UMIN000036542
Not yet recruiting
未知
Randomized Phase II study regarding treatment cycles of neo-adjuvant chemotherapy with biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancer - KHBO-1902
KHBO0 sites100 target enrollmentApril 19, 2019
ConditionsResectable Biliary Tract Cancers
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Resectable Biliary Tract Cancers
- Sponsor
- KHBO
- Enrollment
- 100
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Distant metastasis 2\) Double cancer 3\) Interstitial pneumonia 4\) Waterly diarrhea 5\) Active infection except for hepatitis and cholangitis 6\) Several organ dysfunction (Heat failure, Renal failure, Liver failure, GI bleeding, Ileus, Uncontrolled DM) 7\) Pregnancy 8\) Psychic disorder 9\) Allergy 10\) Others
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Randommized Phase II study of the continuous treatment vs. standard treatment with capecitabine in metastatic breast cancer patientsMETASTATIC BREAST CANCERMedDRA version: 7.0Level: LLTClassification code 10027475EUCTR2004-002759-15-ESDr. Miguel Martín
Recruiting
Phase 2
Does Olanzapine improve quality of life in incurable cancer patients?Health Condition 1: C80- Malignant neoplasm without specification of siteHealth Condition 2: C15-C26- Malignant neoplasms of digestive organsHealth Condition 3: C30-C39- Malignant neoplasms of respiratory and intrathoracic organsCTRI/2022/03/041155ational cancer Institute AIIMS
Active, not recruiting
Phase 1
A study to evaluate the switch from prednisone to dexamethasone in prostate cancer patients being treated with abirateroneEUCTR2021-000943-30-ESSOGUG (Spanish Genitourinary Oncologic Group)110
Active, not recruiting
Phase 1
_Patients with liver-only non resectable colorectal metastases.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001493-15-FRICANCER140
Active, not recruiting
Phase 1
on-randomised phase II trial of Sequential Therapy of Imiquimod followed by Vaccination with TA CIN for High Grade VIVIN3EUCTR2005-001824-35-GBniversity of Manchester30